Dasatinib vs GHK-Cu
Side-by-side comparison of Dasatinib and GHK-Cu: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
Dasatinib
GHK-Cu
Dasatinib
Dasatinib (SPRYCEL) is a second-generation oral tyrosine kinase inhibitor (TKI) with FDA approvals for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is…
No vendor price on file.
Full Dasatinib profileGHK-Cu
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, a molecule Pickart and Thaler first pulled out of human plasma in 1973. The free peptide (GHK, C14H24N6O4) weighs about 340.4 Da; bind it 1:1…
Lowest listed price: $34.99 across 7 listings
Full GHK-Cu profileSide-by-side comparison
| Attribute | Dasatinib | GHK-Cu |
|---|---|---|
| Category | Senolytics | Skin, Hair & Aesthetics |
| Research Stage | Preclinical | Approved/marketed as a topical cosmetic ingredient (Copper tripeptide-1) with supporting small human studies. Injectable use is preclinical/off-label, research-use-only, with no human clinical trials. |
| Mechanism of Action | Dasatinib's mechanism of action spans multiple tyrosine kinases with different relevance to oncology versus senolytic applications. Primary kinase targets: Dasatinib is an ATP-competitive inhibitor with high-affinity binding to BCR-ABL fusion kinase, SRC… | GHK-Cu works mostly as a copper shuttle and a signaling peptide. It binds Cu(II) with high affinity (log K around 16.4, close to albumin's 16.2) and can supply or regulate copper for copper-dependent enzymes like SOD1, lysyl oxidase, cytochrome c oxidase, and… |
| Half-Life | — | ~30-60 min (plasma; approximate legacy figure, no robust modern human PK study) |
| Typical Dose Range | — | 200-500 mcg SC daily (community/RUO; no clinically established injectable dose) |
| Dosing Frequency | — | Once daily subcutaneous; some run 5 days on / 2 days off. Topical: 1-2x daily to cleansed skin. |
| Administration | — | Subcutaneous, Topical |
| Side Effects | Dasatinib has a substantial and well-characterized side effect profile from extensive oncologic use. Intermittent senolytic dosing reduces but does not eliminate these risks. Common Side Effects in Chronic Oncologic Dosing (for context): Thrombocytopenia (20%… | Topical GHK-Cu is generally well tolerated; higher-concentration formulations (4-5%) raise the odds of irritation, redness, or stinging. Injectable use has no safety data from controlled trials; the main theoretical concern is copper accumulation with repeated… |
| Molecular Weight | — | Free peptide (GHK): 340.38 Da (C14H24N6O4). Copper complex (GHK-Cu): 401.9 Da (C14H22CuN6O4, neutral 1:1 Cu(II) complex). |
| Common Vial Sizes | — | 50 mg, 100 mg |
Price History
4 data points- OF
- BM
- Half Nattys
- BHG Labs
Dasatinib: potential benefits
- No structured benefit list published.
GHK-Cu: potential benefits
- Stimulates type I collagen synthesis in human fibroblasts at low nanomolar-to-picomolar concentrations (PMID: 3169264)
- Increases glycosaminoglycans (dermatan/chondroitin sulfate) and upregulates decorin in wound models (PMID: 11121126)
- Modulates matrix metalloproteinases and their inhibitors, partially correcting the MMP-9/TIMP-1 imbalance in a smoke-induced emphysema model (PMID: 35936787)
- Drives tissue remodeling and chemoattracts macrophages, mast cells, and capillary cells to injury sites (PMID: 18644225)
- Modulates expression of ~4,000+ human genes via the Broad Institute Connectivity Map, including DNA-repair and antioxidant genes (PMID: 25302294)
- Increases stemness and proliferative potential of epidermal basal cells and keratinocytes (PMID: 23019153)
- Acts as an antioxidant and anti-inflammatory copper regulator in the context of aging (PMID: 22666519)
- Broad skin-regeneration effects on collagen, proteoglycans, MMPs, and immune/endothelial cell recruitment (PMID: 26236730)
Frequently asked
What's the difference between Dasatinib and GHK-Cu?
Dasatinib is a senolytics that dasatinib's mechanism of action spans multiple tyrosine kinases with different relevance to oncology versus senolytic applications. primary kinase targets: dasatinib is an…. GHK-Cu is a skin, hair & aesthetics that ghk-cu works mostly as a copper shuttle and a signaling peptide. it binds cu(ii) with high affinity (log k around 16.4, close to albumin's 16.2) and can supply or regulate copper…. The two differ in mechanism, half-life (not reported vs ~30-60 min (plasma; approximate legacy figure, no robust modern human PK study)), and typical dose range.
Which has the longer half-life, Dasatinib or GHK-Cu?
Dasatinib has a half-life of not reported. GHK-Cu has a half-life of ~30-60 min (plasma; approximate legacy figure, no robust modern human PK study). Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Can you stack Dasatinib and GHK-Cu?
Stacking depends on mechanism overlap, safety profile, and goals. Dasatinib and GHK-Cu should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy Dasatinib or GHK-Cu
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. Every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.